As of 2024-12-14, the EV/EBITDA ratio of Mirati Therapeutics Inc (MRTX) is -5.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MRTX's latest enterprise value is 3,859.11 mil USD. MRTX's TTM EBITDA according to its financial statements is -723.54 mil USD. Dividing these 2 quantities gives us the above MRTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 16.5x | 14.8x |
| Forward P/E multiples | 15.3x - 20.2x | 16.2x |
| Fair Price | (154.12) - (166.50) | (156.70) |
| Upside | -362.6% - -383.6% | -366.9% |
| Date | EV/EBITDA |